These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18398977)

  • 1. Durability of clinical responses to anti-HIV therapies.
    Laurence J
    AIDS Read; 2008 Mar; 18(3):120-1. PubMed ID: 18398977
    [No Abstract]   [Full Text] [Related]  

  • 2. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
    Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
    J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
    [No Abstract]   [Full Text] [Related]  

  • 3. Mortality among urban drug users and the impact of highly active antiretroviral therapy.
    Celentano DD
    Clin Infect Dis; 2005 Sep; 41(6):873-4. PubMed ID: 16107988
    [No Abstract]   [Full Text] [Related]  

  • 4. Interleukin 2 and HIV RNA Levels.
    Go R; Steigbigel R
    Arch Intern Med; 2007 Oct; 167(19):2144-5; author reply 2145. PubMed ID: 17954814
    [No Abstract]   [Full Text] [Related]  

  • 5. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunovirological and therapeutic follow-up of HIV-1/HIV-2-dually seropositive patients.
    Landman R; Damond F; Gerbe J; Brun-Vezinet F; Yeni P; Matheron S
    AIDS; 2009 Jan; 23(3):426-8. PubMed ID: 19114866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative mortality in HIV-infected patients in Denmark, 1995-2005.
    Singer RB; Milano AF
    J Insur Med; 2008; 40(2):116-9. PubMed ID: 19119590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort.
    Collini P; Schwab U; Sarfo S; Obeng-Baah J; Norman B; Chadwick D; Bibby D; Bedu-Addo G
    Clin Infect Dis; 2009 Apr; 48(7):988-91. PubMed ID: 19231976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The good, the bad, and the ugly: providing highly active antiretroviral therapy when it is most difficult.
    Flanigan TP; Mitty JA
    Clin Infect Dis; 2006 Jun; 42(11):1636-8. PubMed ID: 16652322
    [No Abstract]   [Full Text] [Related]  

  • 10. HIV infection in older patients.
    Adeyemi OM; Badri SM; Max B; Chinomona N; Barker D
    Clin Infect Dis; 2003 May; 36(10):1347. PubMed ID: 12746785
    [No Abstract]   [Full Text] [Related]  

  • 11. [New possibilities of the drug therapy of HIV infection].
    Ristola M; Järvinen A
    Duodecim; 1999; 115(20):2249-57. PubMed ID: 11973929
    [No Abstract]   [Full Text] [Related]  

  • 12. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy.
    Bezemer D; de Wolf F; Boerlijst MC; van Sighem A; Hollingsworth TD; Prins M; Geskus RB; Gras L; Coutinho RA; Fraser C
    AIDS; 2008 May; 22(9):1071-7. PubMed ID: 18520351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment: treatment of acute HIV infection--uncertainties about best practice.
    Kassutto S; Rosenberg ES
    AIDS Read; 2005 May; 15(5):250-1. PubMed ID: 15900635
    [No Abstract]   [Full Text] [Related]  

  • 14. Designing and interpreting HIV noninferiority trials in naive and experienced patients.
    Hill A; Sabin C
    AIDS; 2008 May; 22(8):913-21. PubMed ID: 18453850
    [No Abstract]   [Full Text] [Related]  

  • 15. Running with scissors: using antiretroviral therapy without monitoring viral load.
    Smith DM; Schooley RT
    Clin Infect Dis; 2008 May; 46(10):1598-600. PubMed ID: 18419496
    [No Abstract]   [Full Text] [Related]  

  • 16. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
    Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
    Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).
    Beck EJ; Mandalia S; Youle M; Brettle R; Fisher M; Gompels M; Kinghorn G; McCarron B; Pozniak A; Tang A; Walsh J; Williams I; Gazzard B
    Int J STD AIDS; 2008 May; 19(5):297-304. PubMed ID: 18482958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users.
    Wood E; Kerr T; Zhang R; Guillemi S; Palepu A; Hogg RS; Montaner JS
    HIV Med; 2008 Aug; 9(7):503-7. PubMed ID: 18484977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eager Thailand takes on questionable therapies.
    Birmingham K
    Nat Med; 2002 Aug; 8(8):767-8. PubMed ID: 12152015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.